Electron Kebebew

List of Publications by Year
in descending order

194 papers	12,075 citations	30070 54 h-index	29157 104 g-index
195 all docs	195 docs citations	195 times ranked	12810 citing authors

#	Article	IF	Citations
1	Racial disparities in the utilization of parathyroidectomy among patients with primary hyperparathyroidism: Evidence from a nationwide analysis of Medicare claims. Surgery, 2022, 171, 8-16.	1.9	10
2	Factors associated with postoperative complications and costs for adrenalectomy in benign adrenal disorders. Surgery, 2022, 171, 1519-1525.	1.9	5
3	Risk of Fracture Among Older Adults With Primary Hyperparathyroidism Receiving Parathyroidectomy vs Nonoperative Management. JAMA Internal Medicine, 2022, 182, 10.	5.1	26
4	Treatment for Advanced and Metastatic Thyroid Cancer Refractory to Standard Treatmentâ€"We Need to Know the When, What, and Who. JAMA Oncology, 2022, 8, 250.	7.1	0
5	SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas. Cell Reports, 2022, 38, 110453.	6.4	16
6	Kidney Stone Events Following Parathyroidectomy vs Nonoperative Management for Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2801-e2811.	3.6	5
7	Undertreatment of primary hyperparathyroidism in a privately insured US population: Decreasing utilization of parathyroidectomy despite expanding surgical guidelines. Surgery, 2021, 169, 87-93.	1.9	21
8	Probability of positive genetic testing in patients diagnosed with pheochromocytoma and paraganglioma: Criteria beyond a family history. Surgery, 2021, 169, 298-301.	1.9	1
9	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2021, 31, 337-386.	4.5	297
10	Patient Factors Associated With Parathyroidectomy in Older Adults With Primary Hyperparathyroidism. JAMA Surgery, 2021, 156, 334.	4.3	17
11	Adrenal Incidentaloma. New England Journal of Medicine, 2021, 384, 1542-1551.	27.0	59
12	Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumorsâ€"A Cohort Study. Frontiers in Endocrinology, 2021, 12, 653401.	3.5	3
13	Association of Parathyroidectomy With 5-Year Clinically Significant Kidney Stone Events in Patients With Primary Hyperparathyroidism. Endocrine Practice, 2021, 27, 948-955.	2.1	2
14	This Year in Thyroid and Farewell. Thyroid, 2021, 31, 1765-1765.	4.5	0
15	Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy. Surgery, 2020, 167, 224-232.	1.9	11
16	30th Anniversary and The Future of Thyroid. Thyroid, 2020, 30, 1-1.	4.5	1
17	Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. Journal of Gastrointestinal Oncology, 2020, 11, 567-577.	1.4	14
18	Contemporary Management of Anaplastic Thyroid Cancer. Current Treatment Options in Oncology, 2020, 21, 78.	3.0	25

#	Article	IF	Citations
19	Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3285-3294.	3.6	19
20	Comprehensive guidance on the diagnosis and management of primary mesenchymal tumours of the thyroid gland. Lancet Oncology, The, 2020, 21, e528-e537.	10.7	6
21	Adrenal Vein Sampling to Distinguish Between Unilateral and Bilateral Primary Hyperaldosteronism: To ACTH Stimulate or Not?. Journal of Clinical Medicine, 2020, 9, 1447.	2.4	11
22	Editorial: Translational Research in Thyroid Cancer. Frontiers in Endocrinology, 2020, 11, 224.	3.5	0
23	Genetic testing in endocrine surgery: Opportunities for precision surgery. Surgery, 2020, 168, 328-334.	1.9	6
24	Surgery for adrenocortical carcinoma: When and how?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101408.	4.7	21
25	An update on familial nonmedullary thyroid cancer. Endocrine, 2020, 68, 502-507.	2.3	13
26	The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of Surgery, 2020, 271, e21-e93.	4.2	290
27	Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of Surgery, 2020, 271, 399-410.	4.2	33
28	A Combinatorial Strategy for Targeting BRAFV600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib). Clinical Cancer Research, 2020, 26, 2022-2036.	7.0	15
29	Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2020, 27, 519-527.	3.1	7
30	GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3. Oncotarget, 2020, 11, 3354-3370.	1.8	7
31	Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III). Frontiers in Oncology, 2019, 9, 905.	2.8	9
32	NOP53 as A Candidate Modifier Locus for Familial Non-Medullary Thyroid Cancer. Genes, 2019, 10, 899.	2.4	20
33	National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5948-5956.	3.6	19
34	Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. Thyroid, 2019, 29, 530-539.	4.5	8
35	Solutions to Reduce Unnecessary Imagingâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 2243.	7.4	0
36	MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. Journal of Surgical Research, 2019, 243, 1-7.	1.6	11

#	Article	IF	Citations
37	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2019, 9, 53.	2.8	39
38	Reply: Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment. Surgery, 2019, 165, 1246-1247.	1.9	0
39	Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer. JAMA Network Open, 2019, 2, e187754.	5.9	22
40	The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors. European Journal of Radiology, 2019, 112, 130-135.	2.6	20
41	Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer type-specific. American Journal of Surgery, 2019, 218, 14-17.	1.8	0
42	Preoperative systemic inflammatory markers are prognostic indicators in recurrent adrenocortical carcinoma. Journal of Surgical Oncology, 2019, 120, 1450-1455.	1.7	7
43	Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness. Thyroid, 2019, 29, 79-92.	4.5	18
44	High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy. Surgery, 2019, 165, 124-128.	1.9	4
45	Curbing Unnecessary and Wasted Diagnostic Imaging. JAMA - Journal of the American Medical Association, 2019, 321, 245.	7.4	64
46	Distinct genomeâ€wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors. Cancer, 2019, 125, 1247-1257.	4.1	34
47	Aggressive resection of neuroendocrine tumor (NET) liver metastases: NET neutral or gain?. Surgery, 2019, 165, 176-177.	1.9	1
48	Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment. Surgery, 2019, 165, 50-57.	1.9	21
49	Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindauâ€“associated Solid Pancreatic Tumors. Radiology, 2019, 290, 116-124.	7.3	7
50	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. JAMA Surgery, 2019, 154, 40.	4.3	34
51	Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. Annals of Surgery, 2019, 269, 741-747.	4.2	15
52	Frequency and consequence of the recurrent YY1 p.T372R mutation in sporadic insulinomas. Endocrine-Related Cancer, 2018, 25, L31-L35.	3.1	8
53	Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors. Journal of the National Cancer Institute, 2018, 110, 1019-1029.	6.3	18
54	Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo. Clinical Cancer Research, 2018, 24, 4030-4043.	7.0	106

#	Article	IF	Citations
55	In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippelâ€“Lindau Disease. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1631-1638.	3.6	12
56	Ethnic specific differences in endocrine neoplasms: The role of susceptibility genes. American Journal of Surgery, 2018, 215, 1060-1061.	1.8	0
57	Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. Gastroenterology, 2018, 154, 998-1008.e1.	1.3	62
58	A Lymph Node Ratioâ€“Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 187-195.	3.6	18
59	Thyroid Cancer: Is It All in the Genes?. Journal of the National Cancer Institute, 2018, 110, 327-328.	6.3	2
60	Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippelâ€“Lindau Disease. JAMA Oncology, 2018, 4, 124.	7.1	44
61	Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 787-797.	6.4	64
62	Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype. Cancer, 2018, 124, 636-647.	4.1	10
63	Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis. Annals of Surgical Oncology, 2018, 25, 122-130.	1.5	33
64	Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. Surgery, 2018, 163, 31-34.	1.9	34
65	Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. Surgery, 2018, 163, 191-196.	1.9	32
66	Neural monitoring in endocrine neck surgery. Gland Surgery, 2018, 7, S86-S88.	1.1	2
67	Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. Nature Communications, 2018, 9, 4172.	12.8	56
68	ASO Author Reflections: Systemic Inflammatory Markers in Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2018, 25, 874-875.	1.5	1
69	Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Seminars in Oncology, 2018, 45, 232-235.	2.2	22
70	Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3566-3573.	3.6	43
71	68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor. International Journal of Endocrine Oncology, 2018, 5, IJE04.	0.4	14
72	The effect of lithium on the progressionâ€free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy. Clinical Endocrinology, 2018, 89, 481-488.	2.4	5

#	Article	IF	Citations
73	Probability of Positive Genetic Testing Results in Patients with Family History of Primary Hyperparathyroidism. Journal of the American College of Surgeons, 2018, 226, 933-938.	0.5	21
74	Integrated Genomic Analysis of HÃ¼rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell, 2018, 34, 256-270.e5.	16.8	195
75	Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2189-2198.	3.6	17
76	Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. Endocrine, 2018, 61, 422-427.	2.3	8
77	Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response. Oncotarget, 2018, 9, 33030-33042.	1.8	27
78	Unique and Novel Urinary Metabolomic Features in Malignant versus Benign Adrenal Neoplasms. Clinical Cancer Research, 2017, 23, 5302-5310.	7.0	17
79	Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. Clinical Cancer Research, 2017, 23, 5044-5054.	7.0	54
80	Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. European Journal of Endocrinology, 2017, 176, 575-582.	3.7	38
81	Lipofuscin Accumulation in Cortisol-Producing Adenomas With and Without PRKACA Mutations. Hormone and Metabolic Research, 2017, 49, 786-792.	1.5	10
82	11â€Deoxycortisol may be superior to cortisol in confirming a successful adrenal vein catheterization without cosyntropin: a pilot study. International Journal of Endocrine Oncology, 2017, 4, 75-83.	0.4	16
83	To the editor. Npj Genomic Medicine, 2017, 2, 21.	3.8	0
84	Results of Screening in Familial Non-Medullary Thyroid Cancer. Thyroid, 2017, 27, 1017-1024.	4.5	47
85	Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 195-199.	3.6	83
86	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery, 2017, 161, 230-239.	1.9	60
87	A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. Clinical Endocrinology, 2017, 86, 128-133.	2.4	48
88	Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery, 2017, 161, 220-227.	1.9	47
89	Somatic VHL Mutation in a Patient With MEN1-Associated Metastatic Pancreatic Neuroendocrine Tumor Responding to Sunitinib Treatment: A Case Report. Journal of the Endocrine Society, 2017, 1, 1124-1134.	0.2	5
90	Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. International Journal of Surgical Oncology, 2017, 2017, 1-14.	0.6	8

#	Article	IF	Citations
91	LOX is a novel mitotic spindle-associated protein essential for mitosis. Oncotarget, 2016, 7, 29023-29035.	1.8	7
92	Evaluation and management of pancreatic lesions in patients with von Hippelâ€“Lindau disease. Nature Reviews Clinical Oncology, 2016, 13, 537-549.	27.6	72
93	Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers. Clinical Cancer Research, 2016, 22, 4491-4504.	7.0	50
94	The Rate and Clinical Significance of Incidental Thyroid Uptake as Detected by Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography. Thyroid, 2016, 26, 831-835.	4.5	26
95	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482
96	Insulinoma Due to Multiple Pancreatic Microadenoma Localized by Multimodal Imaging. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3559-3563.	3.6	4
97	Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3564-3567.	3.6	10
98	Endocrine tumors associated with the vagus nerve. Endocrine-Related Cancer, 2016, 23, R371-R379.	3.1	9
99	Novel insights into the polycythemiaâ€“paragangliomaâ€“somatostatinoma syndrome. Endocrine-Related Cancer, 2016, 23, 899-908.	3.1	62
100	Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism. Annals of Surgical Oncology, 2016, 23, 701-707.	1.5	22
101	Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3345-3352.	3.6	21
102	⁶⁸Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3575-3581.	3.6	111
103	18F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippelâ€“Lindau Disease. Annals of Surgical Oncology, 2016, 23, 714-721.	1.5	14
104	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. Journal of Nuclear Medicine, 2016, 57, 1949-1956.	5.0	119
105	MicroRNAs in the thyroid. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 603-619.	4.7	47
106	GCM2 -Activating Mutations in Familial Isolated Hyperparathyroidism. American Journal of Human Genetics, 2016, 99, 1034-1044.	6.2	119
107	Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. Endocrine Practice, 2016, 22, 302-314.	2.1	110
108	Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clinical Cancer Research, 2016, 22, 3458-3466.	7.0	73

#	Article	IF	Citations
109	Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis. Surgery, 2016, 159, 1382-1389.	1.9	43
110	⁶⁸Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. Journal of Nuclear Medicine, 2016, 57, 186-191.	5.0	148
111	Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure. Annals of Surgical Oncology, 2016, 23, 416-423.	1.5	39
112	FDG PET/CT Scan and Functional Adrenal Tumors: A Pilot Study for Lateralization. World Journal of Surgery, 2016, 40, 683-689.	1.6	19
113	Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Populationâ€Based Study. World Journal of Surgery, 2016, 40, 697-705.	1.6	43
114	Resection of primary tumor site isÂassociated with prolonged survival inÂmetastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery, 2016, 159, 311-319.	1.9	91
115	Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer. PLoS ONE, 2016, 11, e0149383.	2.5	11
116	Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer. Oncotarget, 2016, 7, 16517-16528.	1.8	18
117	Phase I trial of systemic intravenous infusion of interleukinâ€13â€Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma. Cancer Medicine, 2015, 4, 1060-1068.	2.8	26
118	Reply to most patients with a small papillary thyroid carcinoma enjoy an excellent prognosis and may be managed with minimally invasive therapy or active surveillance. Cancer, 2015, 121, 3365-3366.	4.1	1
119	Midkine concentrations in fineâ€needle aspiration of benign and malignant thyroid nodules. Clinical Endocrinology, 2015, 83, 977-984.	2.4	10
120	Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with lifeâ€threatening compressive symptoms. Head and Neck, 2015, 37, E205-8.	2.0	2
121	Quantitative reverse transcription polymerase chain reaction-based detection of thyroid-specific gene expression in fine-needle aspirate for thyroid cancer recurrence evaluation: A case report and review of the literature. Head and Neck, 2015, 37, E165-E168.	2.0	0
122	miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer. PLoS ONE, 2015, 10, e0130496.	2.5	48
123	Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer. Clinical Cancer Research, 2015, 21, 4123-4132.	7.0	31
124	Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. Endocrine-Related Cancer, 2015, 22, 319-329.	3.1	28
125	American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making. Thyroid, 2015, 25, 760-768.	4.5	204
126	Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. Nucleic Acids Research, 2015, 43, 9327-9339.	14.5	28

#	Article	IF	Citations
127	Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open, 2015, 5, e008248-e008248.	1.9	29
128	Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4498-4504.	3.6	60
129	miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression. Cancer Research, 2015, 75, 367-377.	0.9	67
130	Epigenetic Regulation of the lncRNA MEG3 and Its Target c-MET in Pancreatic Neuroendocrine Tumors. Molecular Endocrinology, 2015, 29, 224-237.	3.7	107
131	Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity. Carcinogenesis, 2015, 36, 420-428.	2.8	28
132	Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. Journal of the American College of Surgeons, 2015, 221, 509-517.	0.5	72
133	GermlineHABP2Mutation Causing Familial Nonmedullary Thyroid Cancer. New England Journal of Medicine, 2015, 373, 448-455.	27.0	128
134	Long-Term Outcome of Bilateral Laparoscopic Adrenalectomy Measured by Disease-Specific Questionnaire in a Unique Group of Patients with Cushingâ€™s Syndrome. Annals of Surgical Oncology, 2015, 22, 699-706.	1.5	13
135	Tumor growth prediction with reaction-diffusion and hyperelastic biomechanical model by physiological data fusion. Medical Image Analysis, 2015, 25, 72-85.	11.6	27
136	Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2015, 21, 3888-3895.	7.0	223
137	Thyroid Cancer and Nonsteroidal Anti-Inflammatory Drug Use: A Pooled Analysis of Patients Older Than 40 Years of Age. Thyroid, 2015, 25, 1355-1362.	4.5	6
138	Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma. Annals of Surgical Oncology, 2015, 22, 714-720.	1.5	9
139	Feasibility of Radio-Guided Surgery with 68Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2015, 22, 676-682.	1.5	23
140	Should small papillary thyroid cancer be observed? A populationâ€based study. Cancer, 2015, 121, 1017-1024.	4.1	51
141	ATR-101 phase 1 clinical study for adrenocortical carcinoma.. Journal of Clinical Oncology, 2015, 33, TPS4585-TPS4585.	1.6	3
142	Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget, 2015, 6, 9073-9085.	1.8	54
143	Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget, 2015, 6, 18038-18049.	1.8	23
144	Management of anaplastic thyroid cancer. Gland Surgery, 2015, 4, 44-51.	1.1	82

#	Article	IF	Citations
145	ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. PLoS ONE, 2014, 9, e101423.	2.5	36
146	miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocrine-Related Cancer, 2014, 21, 517-531.	3.1	91
147	Performance comparison of SNP detection tools with illumina exome sequencing dataâ€"an assessment using both family pedigree information and sample-matched SNP array data. Nucleic Acids Research, 2014, 42, e101-e101.	14.5	50
148	Patient specific tumor growth prediction using multimodal images. Medical Image Analysis, 2014, 18, 555-566.	11.6	57
149	Assessment of Tumor Growth in Pancreatic Neuroendocrine Tumors in von Hippel Lindau Syndrome. Journal of the American College of Surgeons, 2014, 218, 163-169.	0.5	32
150	Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans. Cell Metabolism, 2014, 19, 302-309.	16.2	643
151	An In Vivo Mouse Model of Metastatic Human Thyroid Cancer. Thyroid, 2014, 24, 695-704.	4.5	38
152	A novel staging system for adrenocortical carcinoma better predicts survival in patients with stageÂI/II disease. Surgery, 2014, 156, 1378-1386.	1.9	32
153	Hyperparathyroidism-jaw tumor syndrome: Results of operative management. Surgery, 2014, 156, 1315-1325.	1.9	68
154	Prospective Evaluation of the Clinical Utility of 18-Fluorodeoxyglucose PET CT Scanning in Patients with Von Hippel-Lindauâ€"Associated Pancreatic Lesions. Journal of the American College of Surgeons, 2014, 218, 997-1003.	0.5	14
155	A Multidisciplinary journal focused on endocrine oncology. International Journal of Endocrine Oncology, 2014, 1, 1-1.	0.4	0
156	MiR-20a Is Upregulated in Anaplastic Thyroid Cancer and Targets LIMK1. PLoS ONE, 2014, 9, e96103.	2.5	57
157	Detection of insulinoma using (68)Gallium-DOTATATE PET/CT: a case report. Gland Surgery, 2014, 3, E1-5.	1.1	9
158	Prospective screening in familial nonmedullary thyroid cancer. Surgery, 2013, 154, 1194-1198.	1.9	26
159	Tumor growth modeling based on dual phase CT and FDG-PET. , 2013, , .		3
160	Multimodal Image Driven Patient Specific Tumor Growth Modeling. Lecture Notes in Computer Science, 2013, 16, 283-290.	1.3	6
161	Repurposing existing drugs for the treatment of thyroid cancer. Expert Review of Endocrinology and Metabolism, 2012, 7, 369-371.	2.4	2
162	DNA Methylation Profiling Identifies Global Methylation Differences and Markers of Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1004-E1013.	3.6	98

#	Article	IF	Citations
163	Robotic Posterior Retroperitoneal Adrenalectomy: For What Benefit and at What Cost?. Archives of Surgery, 2012, 147, 275.	2.2	0
164	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2012, 22, 1104-1139.	4.5	717
165	Anaplastic thyroid cancer: Rare, fatal, and neglected. Surgery, 2012, 152, 1088-1089.	1.9	34
166	Quantitative High-Throughput Drug Screening Identifies Novel Classes of Drugs with Anticancer Activity in Thyroid Cancer Cells: Opportunities for Repurposing. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E319-E328.	3.6	34
167	Prevalence, Clinicopathologic Features, and Somatic Genetic Mutation Profile in Familial Versus Sporadic Nonmedullary Thyroid Cancer. Thyroid, 2011, 21, 367-371.	4.5	127
168	Nile Red Staining Helps Select Cells with Adrenocortical Progenitor Cell-Like Phenotype. Journal of Surgical Research, 2010, 161, 34-35.	1.6	0
169	Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer. Thyroid, 2009, 19, 953-956.	4.5	77
170	Introduction to Papers Presented at the Orlo H. Clark Festschrift. World Journal of Surgery, 2009, 33, 368-368.	1.6	0
171	Clinical Features and Genetic Predisposition to Hereditary Nonmedullary Thyroid Cancer. Thyroid, 2009, 19, 1343-1349.	4.5	104
172	Hereditary Nonâ€medullary Thyroid Cancer. World Journal of Surgery, 2008, 32, 678-682.	1.6	51
173	Adrenocortical carcinoma in the United States. Cancer, 2008, 113, 3130-3136.	4.1	426
174	The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer. Annals of Surgery, 2007, 246, 466-471.	4.2	407
175	Patients with differentiated thyroid cancer have a venous gradient in thyroglobulin levels. Cancer, 2007, 109, 1078-1081.	4.1	7
176	Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?. World Journal of Surgery, 2006, 30, 872-878.	1.6	372
177	A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery, 2006, 140, 960-967.	1.9	104
178	Predictors of Single-Gland vs Multigland Parathyroid Disease in Primary Hyperparathyroidism. Archives of Surgery, 2006, 141, 777.	2.2	155
179	Extent of Disease and Practice Patterns for Medullary Thyroid Cancer. Journal of the American College of Surgeons, 2005, 200, 890-896.	0.5	77
180	Anaplastic thyroid carcinoma. Cancer, 2005, 103, 1330-1335.	4.1	556

#	Article	IF	Citations
181	Id1 Gene Expression and Regulation in Human Thyroid Tissue. Thyroid, 2005, 15, 522-530.	4.5	4
182	Tertiary Hyperparathyroidism. Archives of Surgery, 2004, 139, 974.	2.2	83
183	GCMB gene, a master regulator of parathyroid gland development, expression, and regulation in hyperparathyroidism. Surgery, 2004, 136, 1261-1266.	1.9	39
184	Locally advanced differentiated thyroid cancer. Surgical Oncology, 2003, 12, 91-99.	1.6	59
185	Parathyroidectomy for primary hyperparathyroidism in octogenarians and nonagenarians. Archives of Surgery, 2003, 138, 867.	2.2	69
186	Results of Laparoscopic Adrenalectomy for Suspected and Unsuspected Malignant Adrenal Neoplasms. Archives of Surgery, 2002, 137, 948.	2.2	212
187	Coexisting Chronic Lymphocytic Thyroiditis and Papillary Thyroid Cancer Revisited. World Journal of Surgery, 2001, 25, 632-637.	1.6	193
188	Parathyroid carcinoma. Current Treatment Options in Oncology, 2001, 2, 347-354.	3.0	106
189	Laparoscopic Adrenalectomy: The Optimal Surgical Approach. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2001, 11, 409-413.	1.0	92
190	Medullary thyroid carcinoma. Cancer, 2000, 88, 1139-1148.	4.1	555
191	Medullary thyroid cancer. Current Treatment Options in Oncology, 2000, 1, 359-367.	3.0	61
192	Total Thyroidectomy or Thyroid Lobectomy in Patients with Low-risk Differentiated Thyroid Cancer: Surgical Decision Analysis of a Controversy Using a Mathematical Model. World Journal of Surgery, 2000, 24, 1295-1302.	1.6	72
193	Differentiated Thyroid Cancer: â€œCompleteâ€•Rational Approach. World Journal of Surgery, 2000, 24, 942-951.	1.6	166
194	Phenylacetate Inhibits Growth and Vascular Endothelial Growth Factor Secretion in Human Thyroid Carcinoma Cells and Modulates Their Differentiated Function¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2840-2847.	3.6	21